VRIO Analysis of Cyclopharm Limited

Posted by Zachary Edwards on Mar-22-2018

The VRIO Analysis of Cyclopharm Limited will look at each of its internal resources one by one to assess whether these provide sustained competitive advantage. The Cyclopharm Limited VRIO Analysis also mentions at each stage whether these resources could be improved to provide a greater competitive advantage. Lastly, the resources analysed are summarised as to whether they offer sustained competitive advantage, has an unused competitive advantage, temporary competitive advantage, competitive parity or competitive disadvantage.

Valuable

• The Cyclopharm Limited VRIO Analysis shows that the financial resources of Cyclopharm Limited are highly valuable as these help in investing into external opportunities that arise. These also help Cyclopharm Limited in combating external threats.
• According to the VRIO Analysis of Cyclopharm Limited, its local food products are a valuable resource as these are highly differentiated. This makes the perceived value for these by customers high. These are also valued more than the competition by customers due to the differentiation in these products.
• The Cyclopharm Limited VRIO Analysis shows that Cyclopharm Limited's employees are a valuable resource to the firm. A significant portion of the workforce is highly trained, and this leads to more productive output for the organisation. The employees are also loyal, and retention levels for the organisation are high. All of this translates into greater value for the end consumers of Cyclopharm Limited's products.
• According to the VRIO Analysis of Cyclopharm Limited, its patents are a valuable resource as these allow the firm to sell its products without competitive interference. This results in greater revenue for Cyclopharm Limited. These patents also provide Cyclopharm Limited with licensing revenue when it licenses these patents out to other manufacturers.
• The Cyclopharm Limited VRIO Analysis shows that Cyclopharm Limited’s distribution network is a valuable resource. This helps it in reaching out to more and more customers. This ensures greater revenues for Cyclopharm Limited. It also ensures that promotion activities translate into sales as the products are easily available.
• According to the VRIO Analysis of Cyclopharm Limited, its cost structure is not a valuable resource. This is because the methods of production lead to greater costs than that of competition, which affects the overall profits of the firm. Therefore, its cost structure is a competitive disadvantage that needs to be worked on.
• The Cyclopharm Limited VRIO Analysis shows that the research and development at Cyclopharm Limited is not a valuable resource. This is because research and development are costing more than the benefits it provides in the form of innovation. There have been very few innovative features and breakthrough products in the past few years. Therefore, research and development are a competitive disadvantage for Cyclopharm Limited. It is recommended that the research and development teams are improved, and costs are cut for these.

Rare

• The financial resources of Cyclopharm Limited are found to be rare according to the VRIO Analysis of Cyclopharm Limited. Strong financial resources are only possessed by a few companies in the industry.
• The local food products are found to be not rare as identified by Cyclopharm Limited VRIO Analysis. These are easily provided in the market by other competitors. This means that competitors can use these resources in the same way as Cyclopharm Limited and inhibit competitive advantage. This means that the local food products result in competitive parity for Cyclopharm Limited. As this resource is valuable, Cyclopharm Limited can still make use of this resource.
• The employees of Cyclopharm Limited are a rare resource as identified by the VRIO Analysis of Cyclopharm Limited. These employees are highly trained and skilled, which is not the case with employees in other firms. The better compensation and work environment ensure that these employees do not leave for other firms.
• The patents of Cyclopharm Limited are a rare resource as identified by the Cyclopharm Limited VRIO Analysis. These patents are not easily available and are not possessed by competitors. This allows Cyclopharm Limited to use them without interference from the competition.
• The distribution network of Cyclopharm Limited is a rare resource as identified by the VRIO Analysis of Cyclopharm Limited. This is because competitors would require a lot of investment and time to come up with a better distribution network than that of Cyclopharm Limited. These are also possessed by very few firms in the industry.

Imitable

• The financial resources of Cyclopharm Limited are costly to imitate as identified by the Cyclopharm Limited VRIO Analysis. These resources have been acquired by the company through prolonged profits over the years. New entrants and competitors would require similar profits for a long period of time to accumulate these amounts of financial resources.
• The local food products are not that costly to imitate as identified by the VRIO Analysis of Cyclopharm Limited. These can be acquired by competitors as well if they invest a significant amount in research and development. These also do not require years long experience. Therefore, the local food products by Cyclopharm Limited provide it with a temporary competitive advantage that competitors can too acquire in the long run.
• The employees of Cyclopharm Limited are also not costly to imitate as identified by the Cyclopharm Limited VRIO Analysis. This is because other firms can also train their employees to improve their skills. These companies can also hire employees from Cyclopharm Limited by offering better compensation packages, work environment, benefits, growth opportunities etc. This makes the employees of Cyclopharm Limited a resource that provides a temporary competitive advantage. Competition can acquire these in the future.
• The patents of Cyclopharm Limited are very difficult to imitate as identified by the VRIO Analysis of Cyclopharm Limited. This is because it is not legally allowed to imitate a patented product. Similar resources to be developed and getting a patent for them is also a costly process.
• The distribution network of Cyclopharm Limited is also very costly to imitate by competition as identified by the Cyclopharm Limited VRIO Analysis. This has been developed over the years gradually by Cyclopharm Limited. Competitors would have to invest a significant amount if they are to imitate a similar distribution system.

Organisation

• The financial resources of Cyclopharm Limited are organised to capture value as identified by the VRIO Analysis of Cyclopharm Limited. These resources are used strategically to invest in the right places; making use of opportunities and combatting threats. Therefore, these resources prove to be a source of sustained competitive advantage for Cyclopharm Limited.
• The Patents of Cyclopharm Limited are not well organised as identified by the Cyclopharm Limited VRIO Analysis. This means that the organisation is not using these patents to their full potential. An unused competitive advantage exists that can be changed into a sustainable competitive advantage if Cyclopharm Limited starts selling patented products before the patents expire.
• The distribution network of Cyclopharm Limited is organised as identified by the VRIO Analysis of Cyclopharm Limited. Cyclopharm Limited uses this network to reach out to its customers by ensuring that products are available on all of its outlets. Therefore, these resources prove to be a source of sustained competitive advantage for Cyclopharm Limited.

From the VRIO Analysis of Cyclopharm Limited, it was identified that the financial resources and distribution network provide a sustained competitive advantage. The patents are a source of unused competitive advantage. There exists a temporary competitive advantage for employees. There exists a competitive parity for local food products. Lastly, the cost structure of Cyclopharm Limited is a competitive disadvantage. Research and Development is also a competitive disadvantage.